Evolution of Early SARS-CoV-2 and Cross-Coronavirus Immunity
ABSTRACT The novel coronavirus, SARS-coronavirus (CoV)-2 (SARS-CoV-2), has caused over 17 million infections in just a few months, with disease manifestations ranging from largely asymptomatic infection to critically severe disease. The remarkable spread and unpredictable disease outcomes continue t...
Main Authors: | Carolin Loos, Caroline Atyeo, Stephanie Fischinger, John Burke, Matthew D. Slein, Hendrik Streeck, Douglas Lauffenburger, Edward T. Ryan, Richelle C. Charles, Galit Alter |
---|---|
Format: | Article |
Language: | English |
Published: |
American Society for Microbiology
2020-10-01
|
Series: | mSphere |
Subjects: | |
Online Access: | https://journals.asm.org/doi/10.1128/mSphere.00622-20 |
Similar Items
-
Evolution of Early SARS-CoV-2 and Cross-Coronavirus Immunity
by: Loos, Carolin, et al.
Published: (2020) -
Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination
by: Matthew J. Gorman, et al.
Published: (2021-09-01) -
Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity
by: Kathryn A. Bowman, et al.
Published: (2022-10-01) -
Extra-Neutralizing FcR-Mediated Antibody Functions for a Universal Influenza Vaccine
by: Carolyn M. Boudreau, et al.
Published: (2019-03-01) -
Dissecting Fc signatures of protection in neonates following maternal influenza vaccination in a placebo-controlled trial
by: Carolyn M. Boudreau, et al.
Published: (2022-02-01)